IS8266A - Breytt mennsk IGF-1R mótefni - Google Patents

Breytt mennsk IGF-1R mótefni

Info

Publication number
IS8266A
IS8266A IS8266A IS8266A IS8266A IS 8266 A IS8266 A IS 8266A IS 8266 A IS8266 A IS 8266A IS 8266 A IS8266 A IS 8266A IS 8266 A IS8266 A IS 8266A
Authority
IS
Iceland
Prior art keywords
antibody
modified human
human igf
igf
modified
Prior art date
Application number
IS8266A
Other languages
English (en)
Inventor
David Cohen Bruce
Bedian Vahe
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of IS8266A publication Critical patent/IS8266A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
IS8266A 2003-08-13 2006-01-26 Breytt mennsk IGF-1R mótefni IS8266A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49520003P 2003-08-13 2003-08-13
PCT/IB2004/002555 WO2005016967A2 (en) 2003-08-13 2004-08-03 Modified human igf-1r antibodies

Publications (1)

Publication Number Publication Date
IS8266A true IS8266A (is) 2006-01-26

Family

ID=34193291

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8266A IS8266A (is) 2003-08-13 2006-01-26 Breytt mennsk IGF-1R mótefni

Country Status (37)

Country Link
US (2) US7371378B2 (is)
EP (1) EP1656391B1 (is)
JP (1) JP4638870B2 (is)
KR (1) KR100825156B1 (is)
CN (1) CN1835975B (is)
AP (1) AP2006003510A0 (is)
AR (1) AR045247A1 (is)
AT (1) ATE484525T1 (is)
AU (1) AU2004265152A1 (is)
BR (1) BRPI0413466A (is)
CA (1) CA2535071A1 (is)
CL (1) CL2004002035A1 (is)
CR (1) CR8233A (is)
DE (1) DE602004029581D1 (is)
DK (1) DK1656391T3 (is)
EA (1) EA200600234A1 (is)
EC (1) ECSP066359A (is)
ES (1) ES2351395T3 (is)
GT (1) GT200400158A (is)
IL (1) IL173273A (is)
IS (1) IS8266A (is)
MA (1) MA27988A1 (is)
MX (1) MXPA06001634A (is)
NL (1) NL1026829C2 (is)
NO (1) NO20060542L (is)
OA (1) OA13234A (is)
PA (1) PA8608801A1 (is)
PE (1) PE20050339A1 (is)
PL (1) PL1656391T3 (is)
PT (1) PT1656391E (is)
RS (1) RS20060099A (is)
TN (1) TNSN06050A1 (is)
TW (1) TWI294915B (is)
UA (1) UA85058C2 (is)
UY (1) UY28464A1 (is)
WO (1) WO2005016967A2 (is)
ZA (1) ZA200601231B (is)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME00502B (me) 2001-01-05 2011-10-10 Amgen Fremont Inc Antitjela za insulinu sličan receptor faktora i rasta
NZ554740A (en) 2002-05-24 2009-01-31 Schering Corp Neutralizing human anti-IGFR antibody
EP1622942B1 (en) * 2003-05-01 2014-11-19 ImClone LLC Fully human antibodies directed against the human insulin-like growth factor-1 receptor
EP1656391B1 (en) * 2003-08-13 2010-10-13 Pfizer Products Inc. Modified human igf-1r antibodies
CA2545755A1 (en) 2003-11-12 2005-05-26 Schering Corporation Plasmid system for multigene expression
AR046639A1 (es) 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
KR20070036130A (ko) 2004-07-16 2007-04-02 화이자 프로덕츠 인코포레이티드 항-아이지에프-1알 항체를 사용하는 비-혈액학적악성종양에 대한 조합 치료
FR2873699B1 (fr) * 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
ES2356830T3 (es) 2004-12-03 2011-04-13 Schering Corporation Biomarcadores para preselección de pacientes para terapia de anti-igf-1r.
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
GB0500417D0 (en) * 2005-01-10 2005-02-16 Cambridge Antibody Tech Method of mutagenesis
NZ561648A (en) * 2005-04-15 2009-11-27 Schering Corp Methods and composition of IGF1R inhibitors for treating or preventing cancer
KR20080019249A (ko) * 2005-06-15 2008-03-03 쉐링 코포레이션 안정한 항체 제형
SI2100618T1 (sl) 2005-06-17 2014-03-31 Imclone Llc Antagonisti receptorja za zdravljenje metastaznega kostnega raka
FR2888850B1 (fr) 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
CN101484587B (zh) * 2006-02-03 2014-02-12 英克隆有限责任公司 Igf-ir拮抗剂作为辅药用于前列腺癌的治疗
CA2647111A1 (en) * 2006-03-28 2007-10-04 F. Hoffmann-La Roche Ag Anti-igf-1r human monoclonal antibody formulation
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
WO2007141626A1 (en) 2006-06-02 2007-12-13 Pfizer Products Inc. Circulating tumor cell assay
TW200833711A (en) * 2006-12-22 2008-08-16 Genentech Inc Antibodies to insulin-like growth factor receptor
GB0702888D0 (en) * 2007-02-14 2007-03-28 Glaxo Group Ltd Novel Antibodies
AU2012203443B2 (en) * 2007-03-02 2014-03-06 Amgen Inc. Methods and compositions for treating tumor diseases
JP2010520204A (ja) * 2007-03-02 2010-06-10 アムジェン インコーポレイテッド 腫瘍疾患を治療するための方法および組成物
BRPI0809112A2 (pt) * 2007-03-22 2014-08-26 Imclone Llc Formulações estáveis de anticorpos
EP2145021A2 (en) 2007-05-17 2010-01-20 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
ES2388017T3 (es) 2007-12-21 2012-10-05 Roche Glycart Ag Ensayo de estabilidad de anticuerpos
WO2009142810A2 (en) * 2008-03-25 2009-11-26 Schering Corporation Methods for treating or preventing colorectal cancer
MX2010012064A (es) * 2008-05-05 2010-12-06 Schering Corp Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer.
EP2356154A4 (en) * 2008-11-06 2012-12-19 Alexion Pharma Inc DEVELOPMENT OF REDUCED IMMUNOGENICITY ANTIBODIES AND METHODS OF MANUFACTURING THEREOF
JP2012518657A (ja) 2009-02-25 2012-08-16 オーエスアイ・ファーマシューティカルズ，エルエルシー 併用抗癌治療
EP2236139A1 (en) 2009-03-31 2010-10-06 F. Hoffmann-La Roche AG Combination therapy of erlotinib with an anti-IGF-1R antibody, which does not inhibit binding of insulin to the insulin receptor
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
TWI513465B (zh) 2009-06-25 2015-12-21 Regeneron Pharma 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
AU2010311567B2 (en) 2009-10-26 2015-03-26 Chugai Seiyaku Kabushiki Kaisha Method for the production of a glycosylated immunoglobulin
EP2494070A2 (en) 2009-10-30 2012-09-05 Bristol-Myers Squibb Company Methods for treating cancer in patients having igf-1r inhibitor resistance
AU2014262201B2 (en) * 2009-12-23 2016-09-15 Novartis Ag Method for decreasing immunogenicity
EP2516461A1 (en) 2009-12-23 2012-10-31 ESBATech, an Alcon Biomedical Research Unit LLC Method for decreasing immunogenicity
WO2011101328A2 (en) 2010-02-18 2011-08-25 Roche Glycart Ag Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor
WO2011161119A1 (en) 2010-06-22 2011-12-29 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
CA2804185C (en) 2010-07-12 2017-03-21 Covx Technologies Ireland Limited Multifunctional antibody conjugates
JP2014510265A (ja) 2011-02-02 2014-04-24 アムジェン インコーポレイテッド Ｉｇｆ−１ｒの阻害に関する方法および組成物
ES2724801T3 (es) 2011-04-19 2019-09-16 Pfizer Combinaciones de anticuerpos anti-4-1BB y anticuerpos inductores de ADCC para el tratamiento del cáncer
EP2766497A1 (en) 2011-10-13 2014-08-20 Bristol-Myers Squibb Company Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
ES2700398T3 (es) 2012-01-09 2019-02-15 Pfizer Healthcare Ireland Anticuerpos mutantes y conjugación de los mismos
EP2631653A1 (en) 2012-02-24 2013-08-28 Charité - Universitätsmedizin Berlin Identification of modulators of binding properties of antibodies reactive with a member of the insulin receptor family
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
BR112015010240A2 (pt) * 2012-11-06 2017-08-22 Medimmune Ltd Terapias de combinação através do uso de mo-léculas de ligação de psl e de pcrv anti-pseudomonas
AU2014261630B2 (en) 2013-04-29 2019-05-09 F. Hoffmann-La Roche Ag Human FcRn-binding modified antibodies and methods of use
CN103319598B (zh) * 2013-05-13 2014-10-22 杭州德同生物技术有限公司 抗胰岛素样生长因子-1受体抗体及其编码基因和应用
MX2016008782A (es) 2014-01-15 2016-09-08 Hoffmann La Roche Variantes de region fc con union mejorada de la proteina a.
KR20200100589A (ko) * 2017-07-27 2020-08-26 아이테오스 테라퓨틱스 에스에이 항-tigit 항체

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9203459D0 (en) * 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
CA2218503C (en) 1995-04-20 2001-07-24 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
CA2761116A1 (en) 1995-04-27 1996-10-31 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
IL118626A0 (en) 1996-06-11 1996-10-16 Xtl Biopharmaceuticals Limited Anti HBV antibody
DE69712496T2 (de) 1996-07-18 2002-08-29 Pfizer Matrix metalloprotease-inhibitoren auf basis von phosphinsäuren
KR20000068248A (ko) 1996-08-23 2000-11-25 디. 제이. 우드, 스피겔 알렌 제이 아릴설포닐아미노 하이드록삼산 유도체
JP2002515511A (ja) 1998-05-15 2002-05-28 イムクローン システムズ インコーポレイティド 放射線及び成長因子レセプター・チロシン・キナーゼのインヒビターを使用するヒト腫瘍の治療
EE05627B1 (et) * 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
JP4841038B2 (ja) 1999-03-25 2011-12-21 アボット ゲーエムベーハー ウント カンパニー カーゲー ヒトｉｌ−１２に結合するヒト抗体およびその産生法
ES1042735Y (es) 1999-04-07 2000-02-16 Martinez Fernando Martinez Vehiculo tripersonal de accionamiento a pedales.
US20030165502A1 (en) 2000-06-13 2003-09-04 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
DE10033869C2 (de) 2000-07-12 2003-07-31 Karlsruhe Forschzent HTS-Kryomagnet und Aufmagnetisierungsverfahren
ME00502B (me) * 2001-01-05 2011-10-10 Amgen Fremont Inc Antitjela za insulinu sličan receptor faktora i rasta
ES2398099T3 (es) 2001-02-19 2013-03-13 Merck Patent Gmbh Anticuerpos anti-EGFR modificados con inmunogenicidad reducida
DE60312639T2 (de) 2002-01-18 2007-11-29 Pierre Fabre Médicament Antikörper gegen igf-ir und ihre verwendungen
CA2483848C (en) 2002-04-30 2012-08-21 Kyowa Hakko Kogyo Co., Ltd. Antibody against human insulin-like growth factor
NZ554740A (en) * 2002-05-24 2009-01-31 Schering Corp Neutralizing human anti-IGFR antibody
GB0212303D0 (en) 2002-05-28 2002-07-10 Isis Innovation Molecular targetting of IGF-1 receptor
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
CN101164616A (zh) 2003-02-13 2008-04-23 辉瑞产品公司 抗-胰岛素样生长因子i受体抗体的用途
CA2518980A1 (en) 2003-03-14 2004-09-30 Pharmacia Corporation Antibodies to igf-i receptor for the treatment of cancers
ES2383014T3 (es) 2003-04-02 2012-06-15 F. Hoffmann-La Roche Ag Anticuerpos contra el factor I de crecimiento similar a insulina y usos de los mismos
EP1656391B1 (en) * 2003-08-13 2010-10-13 Pfizer Products Inc. Modified human igf-1r antibodies

Also Published As

Publication number Publication date
TW200516145A (en) 2005-05-16
AP2006003510A0 (en) 2006-02-28
DK1656391T3 (da) 2011-01-03
EP1656391A2 (en) 2006-05-17
BRPI0413466A (pt) 2006-10-17
CN1835975A (zh) 2006-09-20
ECSP066359A (es) 2006-10-31
US7575746B2 (en) 2009-08-18
JP2007527705A (ja) 2007-10-04
CA2535071A1 (en) 2005-02-24
NO20060542L (no) 2006-05-03
MXPA06001634A (es) 2006-04-28
DE602004029581D1 (de) 2010-11-25
KR20060035796A (ko) 2006-04-26
GT200400158A (es) 2005-07-22
TNSN06050A1 (fr) 2007-10-03
ES2351395T3 (es) 2011-02-04
EP1656391B1 (en) 2010-10-13
PT1656391E (pt) 2010-12-06
IL173273A0 (en) 2006-06-11
WO2005016967A3 (en) 2005-04-14
ATE484525T1 (de) 2010-10-15
US20080181891A1 (en) 2008-07-31
OA13234A (en) 2006-12-13
PA8608801A1 (es) 2005-03-03
US7371378B2 (en) 2008-05-13
CN1835975B (zh) 2012-11-21
UY28464A1 (es) 2005-03-31
JP4638870B2 (ja) 2011-02-23
CL2004002035A1 (es) 2005-06-03
US20050069539A1 (en) 2005-03-31
ZA200601231B (en) 2007-05-30
WO2005016967A2 (en) 2005-02-24
AR045247A1 (es) 2005-10-19
CR8233A (es) 2007-01-18
UA85058C2 (ru) 2008-12-25
NL1026829A1 (nl) 2005-02-15
EA200600234A1 (ru) 2006-08-25
PE20050339A1 (es) 2005-05-17
TWI294915B (en) 2008-03-21
PL1656391T3 (pl) 2011-03-31
MA27988A1 (fr) 2006-07-03
AU2004265152A1 (en) 2005-02-24
IL173273A (en) 2011-10-31
RS20060099A (en) 2008-08-07
NL1026829C2 (nl) 2005-07-05
KR100825156B1 (ko) 2008-04-24

Similar Documents

Publication Publication Date Title
IS8266A (is) Breytt mennsk IGF-1R mótefni
DE602004026768D1 (de) Therapeutische anti-igfr1-antikörper-kombinationen
DK1599504T3 (da) Modificeret antistof
CY2016035I2 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
NO20044347L (no) Anti-alfavbeta6-antistoff
NO2016001I2 (no) Trastuzumab emtansin
DE602004022855D1 (de) Interleukin-10-antikörper
NO20071430L (no) Anti-OX4OL antistoffer
DK1572946T3 (da) Terapeutisk humant monoklonalt anti-IL-1R1-antistof
DE502004003292D1 (de) Flugzeug
DK1809660T3 (da) Thymus-specifikt protein
DE502004011106D1 (de) 6-arylmethyl-substituierte pyrazolopyrimidine
IL172511A0 (en) Specific human antibodies
DE502004012209D1 (de) Einparkhilfe
DE502004009935D1 (de) Substituierte dihydrochinazoline ii
DE602004023341D1 (de) Chronograph
NO20053512D0 (no) IL-8-liknende proteiner
FR2853701B1 (fr) Electrovanne
NO20052608D0 (no) Midkinlignende protein
SI1656391T1 (sl) Modificirana humana IGF-1R protitelesa
DK1494693T3 (da) Cripto-specifikke antistoffer
HK1209139A1 (en) Modified antibody
DE602004012372D1 (de) Fahrradpedal
PT9865T (pt) Asa rotulo
NO20033366D0 (no) Kombibleie